RWE AG’s $6.8 Billion Acquisition of Con Edison Clean Energy Businesses
October 02, 2022
On October 1, 2022, RWE AG (“RWE”), a leading renewable energy company, signed a purchase agreement with Con Edison, Inc. to acquire all shares in Con Edison Clean Energy Businesses, Inc., a leading operator and developer of renewable energy plants in the United States, for a purchase price based on an enterprise value of $6.8 billion. Cravath is representing RWE, alongside Hengeler Mueller, in connection with the transaction.
The Cravath team is led by partner Aaron M. Gruber and includes associates Saagar Kaul, Caroline B. Shinkle and Gary R. Uter on M&A matters; partner Lauren Angelilli and associates Kyle R. Jorstad and Alissa B. Fromkin on tax matters; partner Matthew J. Bobby and associates Jana I. Hymowitz and Cortez Johnson on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; partner Matthew M. Kelly, senior attorney Elizabeth Albert and associates Nicolas Thomson and Somi A. Umolu on finance matters; partner John D. Buretta and of counsel Megan Y. Lew on compliance matters; partner Margaret T. Segall on antitrust matters; of counsel Benjamin G. Joseloff on CFIUS matters; practice area attorney Brian M. Budnick on real estate matters; and associate Carys J. Webb on intellectual property matters. Emily R. Eskin also worked on tax matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2007, Stanford Law SchoolOrder of the Coif
-
M.Phil., 2004, University of CambridgeGates Cambridge Scholar
-
B.S., 2003, Yale Collegesumma cum laude
- New York
Education
Admitted In
-
J.D., 2000, Harvard Law Schoolcum laude
-
B.S., 1996, The Wharton School of the University of Pennsylvaniamagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2012, Harvard Law Schoolmagna cum laude
-
M.A., 2009, University of Pennsylvania
-
B.A., 2009, University of PennsylvaniaPhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1997, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.S., 1994, University of Pennsylvania
-
B.A., 1990, University of Pennsylvania
-
B.A.S., 1990, University of Pennsylvania
- New York
Education
Admitted In
- Photo
-
-
J.D., 2013, New York University School of LawJohn Norton Pomeroy Scholar; Benjamin Butler Scholar; Order of the Coif, magna cum laude
-
A.B., 2006, Dartmouth Collegecum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1996, Georgetown University Law Centercum laude
-
B.A., 1993, University of California, Berkeley
- New York
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 2008, Harvard Law Schoolcum laude
-
A.B., 2003, Harvard Collegemagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2008, Stanford Law SchoolPro Bono Distinction
-
B.A., 2004, New York UniversityPhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1987, Yale Law Schoolwith Honors
-
A.B., 1984, Harvard Collegecum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2010, New York University School of Lawcum laude
-
B.S., 2004, Cornell Universitymagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2011, Benjamin N. Cardozo School of Lawcum laude
-
B.A., 2006, University of Virginia
- New York
Education
Admitted In
Related News
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
September 05, 2024
Frontier’s $20 Billion Acquisition by Verizon
On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.
Deals & Cases
May 07, 2024
Ashland’s Sale of its Nutraceuticals Business to Turnspire Capital Partners
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
April 02, 2024
Endeavor’s $25 Billion Take‑Private Acquisition by Silver Lake
On April 2, 2024, Endeavor Group Holdings, Inc. (“Endeavor”), a global sports and entertainment company, announced that it has entered into a definitive agreement to be acquired by Silver Lake, the global leader in technology investing, in partnership with the Endeavor management team and additional anchor investors. Cravath is representing the independent Special Committee of Endeavor’s board of directors in connection with the transaction.
